Note
The first twelve weeks on a GLP-1
The first three months are mostly escalation. Wegovy injection does not reach its usual 2.4 mg maintenance dose until week 17. Zepbound spends the first four weeks at 2.5 mg, a dose the label says is for initiation and is not a maintenance dose, and only then steps upward. Saxenda climbs daily over about five weeks toward 3 mg. People who judge the drug by week two are judging the starter dose. This note walks those weeks with the labels in hand. It is educational. Your prescriber’s schedule, if it differs because you did not tolerate a step, outranks a calendar printed here.
Before the first dose
Confirm the product name on the box. Wegovy, Ozempic, and Rybelsus are all semaglutide and are not interchangeable. Zepbound and Mounjaro are both tirzepatide and are not a reason to use two of them. The labels say not to combine GLP-1 receptor agonists. Set a weekly day for an injection, or a morning routine for a tablet. Wegovy tablets are taken on an empty stomach with up to 4 ounces of water, then a 30-minute wait. Injections can be taken with or without food.
Read the storage line for the device you were given. Wegovy single-dose pens are refrigerated and should not be frozen. There is a limited out-of-refrigerator window on the label. Do not rely on a group chat for that number. Tell a clinician about pregnancy plans. Wegovy’s label says to stop at least two months before a planned pregnancy for the weight-reduction and cardiovascular uses, and to stop when pregnancy is recognized.
If you want the path that leads up to this first box, the consumer guide Get GLP-1 online describes the evaluation. This notebook starts when the box is already in the house.
Weeks 1 through 4
Wegovy injection is 0.25 mg once weekly. Zepbound is 2.5 mg once weekly. Saxenda starts at 0.6 mg daily and, if tolerated, increases each week. Many people notice fullness, less interest in food, or a wave of nausea, especially after a large or fatty meal. In adult weight-reduction trials, the Wegovy label says gastrointestinal reactions were most often reported during dose escalation. Nausea was reported by 44 percent of people on Wegovy injection versus 16 percent on placebo. Those are group rates. You might have none of them. You might have enough that the next step should wait.
Constipation or diarrhea can show up in this same window. The practical response is smaller meals, fluids, and fiber from ordinary foods, described in what to eat. Do not start a stimulant laxative every day without asking someone who knows your other medicines. Do not “make up” for a low-appetite day by skipping fluids.
Activity in this month can be short. The Physical Activity Guidelines still describe 150 minutes a week of moderate aerobic activity as the adult target, built up rather than started as a punishment. Two short walks and one session of basic strength work, using the major muscle groups, is a coherent start. NIDDK pairs that activity with the eating pattern. Muscle-strengthening on two or more days is the guideline’s language, not a gym membership.
Call sooner than the next visit for warning symptoms on the label: severe abdominal pain that may radiate to the back, vomiting that will not stop, signs of dehydration, or allergic symptoms such as swelling or trouble breathing. UT Southwestern’s FAQ tells patients to take gastrointestinal effects seriously enough to report the severe ones. A dull queasiness that passes is a different message from pain that does not.
Weeks 5 through 8
If the first step was tolerated, Wegovy injection moves to 0.5 mg weekly and Zepbound moves to 5 mg weekly. Saxenda, on its table, is at 3 mg by week 5 if every weekly step was tolerated. This is a common time for nausea to return even if week 3 felt easy, because the dose changed. The Wegovy label says that if a dose during escalation is not tolerated, consider delaying the next increase for four weeks. Zepbound’s label says to consider a lower maintenance dose if a maintenance dose is not tolerated, and the steps themselves are at least four weeks apart. You do not have to be heroic. Tell the prescriber.
Weight change in this month is often visible and often uneven. STEP 1’s coprimary result was at week 68, not week 6. A two-pound week and a flat week can both sit inside a longer downward curve. Daily weighing helps some people and rattles others. If you weigh, look at the direction over weeks. The plateau note is for later, when a real stall has lasted, not for a long weekend.
Food noise, the constant planning of the next meal, is a phrase patients use. Trials measured appetite and intake more formally than that phrase. What you can do with the experience is practical: use the quieter appetite to build a repeatable plate rather than to skip meals entirely. Protein at the start of the meal is the pattern discussed in the eating note, drawn from clinical commentary rather than from a drug label.
Weeks 9 through 12
Wegovy injection moves to 1 mg weekly if the schedule is being followed. Zepbound may move from 5 mg toward 7.5 mg and then 10 mg only on the “at least four weeks” rule, so many people are still at 5 mg or have just reached 7.5 mg by the end of week 12. Do not compare your pen to a friend’s and accelerate to catch up. The escalation tables exist to reduce gastrointestinal adverse reactions.
This is a reasonable time for a planned follow-up. Bring a short record: doses taken, doses missed, nausea or constipation that changed your eating, any vomiting, and how strength work felt. Missed Wegovy injections have a two-day rule. If the next dose is more than two days away, take the missed dose; if less than two days remain, skip it. Two or more missed Wegovy injections in a row may mean restarting escalation lower. Zepbound’s missed dose can be taken within four days, then skipped. Saxenda’s label says that if more than three days have passed since the last dose, restart at 0.6 mg. Those are label instructions to review with the prescriber, not a puzzle to solve in a group chat.
Gallbladder symptoms can appear as weight comes off, not only in week one. Labels report a higher rate of gallstones than placebo and tell patients to report severe abdominal pain, fever, or yellowing of the skin. Hair shedding is listed among common reactions for these drugs and often shows up later than week four. It is a reason to mention nutrition, not a reason to panic or to buy a supplement stack.
What “success” is not, at week 12
It is not the mean percent lost in STEP 1. It is not a dose you were never prescribed. It is not the absence of every side effect. A useful week-12 review asks whether you are tolerating the current dose, whether you are eating enough protein and drinking enough fluid to function, whether other medicines such as insulin needed adjustment, and whether the next labeled step makes sense. The dose tables themselves live on the semaglutide reference. Side effects that need a closer reading are in the side-effects note. If the prescriber pauses escalation, that pause is part of the label, not a failure of the twelve weeks.
Sources we used
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s041lbl.pdf
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206321s024lbl.pdf
- https://pubmed.ncbi.nlm.nih.gov/33567185/
- https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/eating-physical-activity
- https://odphp.health.gov/our-work/nutrition-physical-activity/physical-activity-guidelines/current-guidelines
- https://utswmed.org/medblog/glp1-frequently-asked-questions/